News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2020 Shelley Wood November 30, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020
News Industry News Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure October 27, 2015